European Journal of Cancer
Volume 46, Issue 15 , Pages 2671-2673 , October 2010

A phase 2 study of vatalanib in metastatic melanoma patients

  • Natalie Cook

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Bristi Basu

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Swethajit Biswas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Paula Kareclas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Colette Mann

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Cheryl Palmer

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Anne Thomas

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • Steve Nicholson

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • Bruno Morgan

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • David Lomas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Bhawna Sirohi

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Adrian P. Mander

      Affiliations

    • MRC Biostatistics Unit Hub in Trials Methodology Research, Cambridge, UK
    • ,
  • Mark Middleton

      Affiliations

    • University of Oxford, Department of Medical Oncology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
    • ,
  • Pippa G. Corrie

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • Corresponding Author InformationCorresponding author: Address: Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. Tel.: +44 1223 274401; fax: +44 1223.

Received 25 June 2010 ,Revised 13 July 2010 ,Accepted 14 July 2010.

References 

  1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998–1012
  2. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14(8):2367–2376
  3. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581–586
  4. Fruehauf Jea. Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2008;26;[abstract 9006]
  5. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178–2189
  6. Gauler TCea. Phase II open-label study to investigate efficacy and safety of PTK787 orally administered once daily at 1250mg as second line monotherapy in patients with stage IIIB or IV non-small cell lung cancer. Proc Am Soc Clin Oncol. 2006;24:274s;[abstract 5075]
  7. Thomas AL, Trarbach T, Bartel C, et al. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol. 2007;18(4):782–788
  8. Conrad C. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004;22(14s):1512
  9. Morgan B, Utting JF, Higginson A, et al. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer. 2006;94(10):1420–1427
  10. Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009;45(10):1807–1814

☆ Research Support: This study was sponsored by Cambridge University Hospitals NHS Foundation Trust, adopted by the UK National Cancer Research Institute (NCRI), supported by grants from Bayer Schering Pharma and Addenbrooke’s Charitable Trust. M.R.M. is supported by the NIHR Biomedical Research Centre, Oxford.

PII: S0959-8049(10)00692-1

doi: 10.1016/j.ejca.2010.07.014

European Journal of Cancer
Volume 46, Issue 15 , Pages 2671-2673 , October 2010

Article Tools